ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its
financial results for the third quarter of 2014 on Monday, November 10,
2014 at 7:00 a.m. Eastern Time. The Company will hold a conference call
at 9:00 a.m. Eastern Time that day to discuss these results.
|
Conference Call and Webcast
|
|
|
|
|
|
|
Date:
|
Monday, November 10, 2014
|
|
|
|
|
|
Time:
|
9:00 a.m., Eastern Time
|
|
|
|
Conference Call Numbers
|
|
|
|
|
|
|
Domestic (toll free):
|
(877) 868-1831
|
|
|
|
|
|
International:
|
(914) 495-8595
|
|
|
|
|
|
Webcast:
|
http://investors.arqule.com/index.cfm
|
A replay of the conference call will be available beginning two hours
after the completion of the call until the end of November 12, 2014 and
can be accessed by dialing toll-free 855-859-2056 or 800-585-8367, and
from outside the U.S. 404-537-3406. The confirmation code for replayed
calls is 15276449.
About ArQule
ArQule is a biotechnology company engaged in the research and
development of next-generation, small-molecule cancer therapeutics. The
Company’s targeted, broad-spectrum products and research programs are
focused on key biological processes that are central to human cancers.
ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is
tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor
tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to
inhibit the AKT serine/threonine kinase, and ARQ 087, a multi-kinase
inhibitor designed to preferentially inhibit the fibroblast growth
factor receptor (FGFR) family. ArQule’s current discovery efforts are
focused on the identification of novel kinase inhibitors, leveraging the
Company’s proprietary library of compounds.
Copyright Business Wire 2014